Insuhn detemir

Insuhn detemir has been on the market for a short period, and no concerns are registered in the few pregnancies using detemir observed. A large randomized study investigating the efficacy and safety of using insulin detemir are initiated in spring 2007, and the data are expected to be available in 2010. 

Fig. 1. Trends in the use of insuhn in Denmark in the new millennium, all insuhns (defined daily doses, DDD) (A), fast-acting insuhns (left human insuhn, middle lispro, right aspart) (B), basal insuhns (left glargine, middle detemir, right human insuhn) (C). (From The Danish Medicines Agency at www.dkma.dk.) The numbers reflect the use of insuhn in 44,467 patients in 2001, increasing to 56,501 in 2005. Total use of analogues is increasing.

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin bound basal insulin analogues (insulin detemir and NN344) comparable time-action profiles but less variabihty than insuhn glargine in type 2 diabetes. Diabetes Obes Metab 2007 9(3) 290-299. 

In a second smdy detemir plus aspart was compared with NPH and hnman fast-acting insuhn [47]. Nocturnal hypoglycaemia weight gain and... 

Figure 5.5 Primary structures of (a) human insulin (mol wtmonoisotopic = 5803.6 Da), (b) Humalog LisPro (mol wt, onoisotopic = 5803.6 Da), (c) Novolog Aspart (mol wt ono otopic = 5821.6Da), (d) Glulisine Apidra (mol whnonoisotopic = 5818.6Da), (e) Lantus Glargine (mol wtmonoisotopic = 6058.8Da), and (f) Detemir (mol wtmonoisoiopic = 5913.8Da). Disulfide bonds are indicated in case of human insuhn (a) only but are present in all synthetic derivatives.

---